Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0TRPYS
ADC Name	Anti-GPC3 ADC
Synonyms	Anti GPC3 ADC Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Hepatocellular carcinoma [ICD11:2C12] Investigative
	3D MOL	2D MOL
Antibody Name	Anti-GPC3 mAb		Antibody Info
Antigen Name	Glypican-3 (GPC3)		Antigen Info
Payload Name	Undisclosed
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI)	≈ 98	%	Hepatocellular carcinoma PDX model (PDX: LI1097)
Tumor Growth Inhibition value (TGI)	≈ 100	%	Hepatocellular carcinoma PDX model (PDX: LI1068)
Tumor Growth Inhibition value (TGI)	≈ 100	%	Hepatocellular carcinoma PDX model (PDX: LI1037)

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.00% (Day 42)	High GPC1 expression(GPC1+++)
Method Description	Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model	Hepatocellular carcinoma PDX model (PDX: LI1097)
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 100)	High GPC1 expression(GPC1+++)
Method Description	Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model	Hepatocellular carcinoma PDX model (PDX: LI1068)
Experiment 3 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 53)	High GPC1 expression(GPC1+++)
Method Description	Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model	Hepatocellular carcinoma PDX model (PDX: LI1037)

References

Ref 1	A novel semi-mechanistic tumor growth fraction model for translation of preclinical efficacy of anti-glypican 3 antibody drug conjugate to human. Biopharm Drug Dispos. 2020 Nov;41(8-9):319-333. doi: 10.1002/bdd.2249. Epub 2020 Aug 19.